医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Novālent Launches Patented US Technology in Australia & New Zealand Markets to Help Fight COVID-19

2020年11月05日 PM10:00
このエントリーをはてなブックマークに追加


 

GREENSBORO, N.C.

Novālent Biotech, Inc (‘Novālent’), a US biotechnology engineering firm, announces it is launching its patented surface disinfectant products in Australia and New Zealand.

Novālent technology protects against bacteria and viruses on surfaces for up to 90 days. The antimicrobial is applied to surfaces by wiping, spraying, or fogging. Once dry, the surface remains protected even if touched or recontaminated multiple times.

Even routine disinfecting does not diminish Novālent’s protective properties. The technology is based on a patented non-toxic monomolecular layer that provides up to 90 days of antimicrobial protection. Novālent products have applications across industries including buildings and facilities, food service, hospitality, fitness, healthcare, transport, and textiles and apparel.

“We’ve seen a rapid adoption of our technology in the US from market leaders including PepsiCo, Hanesbrands, and Pilgrim’s,” said Kevin Parrish, CEO of Novālent. “We are now bringing this technology to the Australia and New Zealand market to provide customers with a truly revolutionary product based on more than two decades of research by our R&D engineering team in the US.”

The Australian Therapeutic Goods Administration (TGA) has registered Novālent technology as an effective commercial-grade surface disinfectant against coronaviruses including the virus that causes COVID-19.

About Novālent

Novālent® is a leading U.S. biotechnology engineering firm which has pioneered the development of proprietary, long-lasting technology that protects against germs. Novālent® technology is based on a patented, non-toxic monomolecular layer that continuously inhibits the growth of bacteria for up to 90 days on surfaces. Used by leading US firms including PepsiCo, Pilgrims and HanesBrands, Novālent is private equity-backed and is headquartered in Greensboro, North Carolina, with five offices around the world. Visit www.novalent.com for more information.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201105005576/en/

CONTACT

Christine Pietryla Wetzler

christine@pietrylapr.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • Sherlock Biosciences Strengthens Intellectual Property Portfolio in CRISPR-based Diagnostics Through Exclusive License Agreement with Tolo Biotech
  • New Phase 3 Data Show TAK-620 (maribavir), an Investigational Drug for the Treatment of Transplant Recipients with Refractory/Resistant Cytomegalovirus (CMV) Infections, Meets Primary Endpoint
  • Shape Therapeutics推出AAVid™衣壳发现平台和新型组织特异性AAV变异识别,解决基因治疗根本性的投药挑战
  • 三叶草生物发布其“S-三聚体”重组亚单位新冠候选疫苗 I 期临床研究积极结果
  • Clover Biopharmaceuticals Announces Positive Phase 1 Data for its Adjuvanted S-Trimer COVID-19 Vaccine Candidates